Apr 11Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference
Mar 18Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
Feb 7Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update
Feb 1Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024
Jan 24Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX® 3-71 in Humans
Jan 8Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders